Funding that library
2 June 2009

The IrishAmerican biotech faces a 2011 cash crunch. So selling a minority stake, to Pfizer or Bristol, makes sense given its intriguing but unfunded drugs pipeline. Moreover, the wave of pharma consolidation could hinder a full sale.